|GenoMed's Method to Prevent Most Kidney Dialysis Featured on IKIDNEY.COM|
Contact: David Moskowitz MD GenoMed, Inc. tel. 314-983-9933 email@example.com
ST. LOUIS--June 21, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that its method to prevent up to 90% of kidney dialysis was featured in the latest version of NEPHROLOGY Incite, a newsletter for kidney patients at www.IKIDNEY.com.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, was interviewed about his work on angiotensin I-converting enzyme (ACE). Said Dr. Moskowitz, "Using higher than usual doses of certain ACE inhibitors can actually reverse chronic kidney failure. But this approach must be started while a person's serum creatinine is below 2. A normal serum creatinine is less than 1.5. Patients aren't referred to a kidney specialist until their creatinine is close to 3. So it's imperative that patients learn about this before it's too late for them."
The full interview is at:
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.